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Pain alters opioid reinforcement, presumably via neuroadaptations within ascending pain
pathways interacting with the limbic system. Nerve injury increases expression of glu-
tamate receptors and their associated Homer scaffolding proteins throughout the pain
processing pathway. Homer proteins, and their associated glutamate receptors, regulate
behavioral sensitivity to various addictive drugs. Thus, we investigated a potential role for
Homers in the interactions between pain and drug reward in mice. Chronic constriction
injury (CCI) of the sciatic nerve elevated Homer1b/c and/or Homer2a/b expression within all
mesolimbic structures examined and for the most part, the Homer increases coincided with
elevated mGluR5, GluN2A/B, and the activational state of various down-stream kinases.
Behaviorally, CCI mice showed pain hypersensitivity and a conditioned place-aversion (CPA)
at a low heroin dose that supported conditioned place-preference (CPP) in naïve controls.
Null mutations of Homer1a, Homer1, and Homer2, as well as transgenic disruption of
mGluR5-Homer interactions, either attenuated or completely blocked low-dose heroin CPP,
and none of the CCI mutant strains exhibited heroin-induced CPA. However, heroin CPP
did not depend upon full Homer1c expression within the nucleus accumbens (NAC), as
CPP occurred in controls infused locally with small hairpin RNA-Homer1c, although intra-
NAC and/or intrathecal cDNA-Homer1c, -Homer1a, and -Homer2b infusions (to best mimic
CCI’s effects) were sufficient to blunt heroin CPP in uninjured mice. However, arguing
against a simple role for CCI-induced increases in either spinal or NAC Homer expression
for heroin CPA, cDNA infusion of our various cDNA constructs either did not affect (intrathe-
cal) or attenuated (NAC) heroin CPA.Together, these data implicate increases in glutamate
receptor/Homer/kinase activity within limbic structures, perhaps outside the NAC, as pos-
sibly critical for switching the incentive motivational properties of heroin following nerve
injury, which has relevance for opioid psychopharmacology in individuals suffering from
neuropathic pain.
Keywords: Homer proteins, Group1 metabotropic glutamate receptors, NMDA receptors, neuropathic pain, heroin,
nucleus accumbens, conditioned place-preference, conditioned place-aversion
INTRODUCTION
Comorbidity exists between chronic pain and motivational dis-
turbances (e.g., Doth et al., 2010; Ohayon and Schatzberg, 2010;
Jarcho et al., 2012; Oluigbo et al., 2012), and a cause-effect rela-
tionship between chronic pain and a blunted motivational state
is apparent also in animal studies (c.f., Niikura et al., 2010). The
pain processing pathway interacts at multiple levels with brain
structures embedded within mesocorticolimbic subcircuits under-
pinning subjective responses to, as well as the incentive value of,
stimuli (both appetitive or noxious), including subregions of the
prefrontal cortex (PFC), nuclei of the amygdala (AMY), the ventral
tegmental area (VTA), and subregions of the nucleus accumbens
(NAC) (c.f., Leknes and Tracey, 2008; Becker et al., 2012). While
the neurocircuitry underpinning pain perception and the subjec-
tive pain response is known to involve activation within several
frontal cortical subregions and thalamus (c.f., Leknes and Tracey,
2008; Oluigbo et al., 2012), the precise neurocircuitry involved in
pain-induced alterations in motivation are less well understood
(Becker et al., 2012).
Patients’ hypersensitivity to pain stimuli correlates with
increases in PFC-NAC connectivity in recent neuroimaging stud-
ies and, importantly, heighted connectivity is predictive of affective
pain, as well as pain severity in humans (e.g., Baliki et al., 2010,
2012). In animal and human studies, noxious stimuli, includ-
ing chronic constriction injury (CCI) of the sciatic nerve, alters
the activational state of mesocorticolimbic circuit (e.g., Kuroda
et al., 1995; Rodella et al., 1998; Narita et al., 2003, 2005; Ozaki
et al., 2003, 2004; Wood et al., 2007). Thus, injury-induced meso-
corticolimbic anomalies are theorized to underpin the negative
affective aspects of pain, as well as the impairments in motivation
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often observed in individuals suffering from chronic somatic
pain (c.f., Leknes and Tracey, 2008; Becker et al., 2012; Oluigbo
et al., 2012). In support of an interaction between a chronic
pain state and drug reinforcement/reward, there is an absence of
both opioid drug- and psychomotor stimulant-induced condi-
tioned place-preference (CPP) in animal models of inflammatory
or neuropathic pain (c.f., Niikura et al., 2010), which is consistent
with very little evidence for the clinical diagnosis of addiction in
individuals undergoing pharmacotherapy for chronic pain symp-
toms (e.g., Niikura et al., 2010; Minozzi et al., 2013). However,
pain symptoms augment opioid drug consumption under oper-
ant procedures in animal models, which is theorized to reflect
a compensation for a depressed mesocorticolimbic circuit (Col-
paert et al., 1982, 2001; Dib and Duclaux, 1982; Lyness et al., 1989;
Martin et al., 2007, 2011), fitting with extant CPP data indicat-
ing blunted drug-conditioned reward following nerve injury (c.f.,
Niikura et al., 2010).
Glutamate neuroadaptations within the mesocorticolim-
bic system are theorized to contribute significantly to drug
reward/reinforcement in various addiction-related animal models
(e.g., Szumlinski et al., 2008; Kalivas, 2009; Olive et al., 2012). As
noxious, painful stimuli augment glutamatergic neurotransmis-
sion both at the spinal and supraspinal levels and glutamatergic
hyperactivity is considered an active mediator of pain sympto-
matology (c.f., Chiechio and Nicoletti, 2012; Harris and Clauw,
2012; Wozniak et al., 2012; Osikowicz et al., 2013), the present
study employed a combination of immunoblotting and behav-
ioral genetic approaches to test the hypothesis that injury-induced
increases in mesocorticolimbic glutamate transmission contribute
to a blunted motivational state within the confines of a heroin CPP
model of drug reward.
MATERIALS AND METHODS
SUBJECTS
Subjects included adult male C57BL/6J (B6) mice (8 weeks of age;
25–30 g; the Jackson Laboratories,Bar Harbor,ME,USA),as well as
several strains of constitutive gene knock-out (KO) mice that were
available at the time of study, including Homer1a KO (Hu et al.,
2012),Homer1 KO (Yuan et al., 2003), and Homer2 KO (Shin et al.,
2003) mice. Knock-in (KI) mice expressing mutant mGluR5 with
a phenylalanine (F) to arginine (R) switch at position 1128 that
markedly reduces mGluR5-Homer interactions (Grm5R/R; Coz-
zoli et al., 2009) were also employed. All the above mutant strains
were bred in-house at UCSB from mating of heterozygous breeder
pairs (B6× 129Xi/SvJ background) and male wild-type (WT),het-
erozygous (HET), and homozygous KO/KI littermate pups were
employed in all studies. For the KO/KI strains bred in-house, mice
were selected from a minimum of four different litters within each
replicate and testing began at 7–8 weeks of age. Experimental pro-
tocols were approved by the IACUCs of our respective institutions
and were consistent with the guidelines provided by NIH and the
Committee for Research and Ethical Issues of IASP.
NEUROPATHIC PAIN, INFLAMMATORY PAIN, AND PAIN THRESHOLD
ASSESSMENT
The procedures for inducing peripheral neuropathy by CCI of
the sciatic nerve were identical to those described recently by our
group (Obara et al., 2013). The total length of nerve affected
was 3–4 mm. Mechanical and cold hypersensitivity at the plan-
tar surface of the hind paw ipsilateral to the injury was assessed,
respectively, using von Frey filaments (0.07–6 g; Stoelting, Wood
Dale, IL, USA) and the acetone test (50µl) before nerve injury (as
one index of basal pain threshold), and on days 3, 7, and/or 14
post-CCI (e.g., Obara et al., 2003, 2013; Osikowicz et al., 2008).
IMMUNOBLOTTING
At 1 or 2 weeks after nerve injury, the entire NAC, the VTA, the
entire AMY, and the PFC (anterior cingulate, prelimbic, and infral-
imbic cortices) were dissected from B6 mice (n= 6–8/group/time-
point) over ice, homogenized in a buffer containing both pro-
tease and phosphatase inhibitors and subjected to conventional
immunoblotting procedures (20µg protein/lane) as described
previously by our group (e.g., Goulding et al., 2011; Obara et al.,
2013). The details regarding the antibodies employed to detect
protein levels of Homer1b/c, Homer2a/b, mGluR1, mGluR5,
GluN2A, GluN2B, PI3K, p(Tyr)PI3K p85α binding motif, ERK1/2,
p(Tyr204)ERK1/2, PKCε, p(Ser729)PKCε, and calnexin (loading
and transfer control) are provided in the legend for Figure 2.
The data for neuropathic animals at the different time-points
post-injury were expressed as a percent change from the mean
signal of the uninjured controls for each individual membrane
(n= 3–4/membrane) as published previously (e.g., Obara et al.,
2013).
HEROIN-INDUCED PLACE-CONDITIONING
Mice were assayed for the development of heroin place-
conditioning, starting at 14 days post-nerve injury. The appara-
tus and procedures for heroin place-conditioning were similar
to those employed in our previous studies of drug-conditioned
reward in mice (e.g., Penzner et al., 2008) and proceeded in the
following four sequential phases: habituation, preconditioning
test (Pre-Test), conditioning, postconditioning test (Post-test). All
sessions were 15 min in duration and animals received no injec-
tions during the habituation, Pre-Test, or Post-Test sessions when
they had free-access to both compartments of the apparatus. For
conditioning, mice received four alternating pairings of distinct
compartments with either intraperitoneal heroin (0.01–3 mg/kg;
vol= 0.01 ml/kg) or an equivalent volume of saline in an unbiased
fashion. Locomotor activity was monitored during all free-access
sessions, as well as on the first and fourth saline/heroin condition-
ing session to index spontaneous and heroin-induced changes in
ambulation, respectively. An increase in heroin-induced locomo-
tion from injections 1–4 indicated the presence of locomotor sen-
sitization. The time spent in the drug-paired vs. -unpaired com-
partment on the Post-Test served to index place-conditioning. The
dose-response study of B6 mice employed 8–9/mice/group/dose,
while the sample sizes employed in the single-dose study of mutant
mice were: 11–15 mice/group/genotype for Homer1a KO, 11–3
mice/group/genotype for Homer1 KO, 8–15 mice/group/genotype
for Homer2 KO, and 12–18 mice/group/genotype for Grm5R/R
mutant.
SURGICAL PROCEDURES AND AAV INFUSION
The procedure for generating neurotropic chimeric AAV1/2 vec-
tors carrying the renilla green fluorescent protein (hrGFP) cDNA
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or the hemagglutinin (HA) tag fused to the coding region of rat
Homer1c, and Homer2b have been described in detail elsewhere
(e.g., Klugmann et al., 2005) and the AAV-cDNA constructs were
identical to those employed previously (e.g., Klugmann et al., 2005;
Tappe et al., 2006; Cozzoli et al., 2009; Goulding et al., 2011; Ary
et al., 2013). The design of the AAV constructs for expression of
small hairpin RNAs (shRNA) against Homer1c were described
in detail in Klugmann and Szumlinski (2008). Briefly, we used a
bicistronic expression cassette entailing the human U6 promoter
to drive the shRNA, followed by the hrGFP reporter under the con-
trol of the chicken-beta actin (CBA) promoter for identification of
transduced neurons. The shRNA-Homer1c construct was the same
as that used in a recently published report, in which we demon-
strated approximately 50% protein knock-down within the brain
at 3 weeks post-infusion (Ary et al., 2013). AAV-shEGFP-CBA-
hrGFP was used as a generic control (GFP) in our AAV studies.
The surgical procedures for intra-NAC AAV infusion (0.5µl/side)
were identical to those used in previous studies (e.g., Cozzoli
et al., 2009) and resulted in placement of microinjectors within
the boundaries of the NAC (see Figure 5A). Studies examining
behavioral response in heroin-induced place-preference test after
intrathecal AAV infusion employed mice whose neuropathic pain
symptoms and AAV transduction patterns within spinal cord were
described before (Obara et al., 2013). Following either intracra-
nial or intrathecal infusion, animals were left undisturbed for
3 weeks when AAV-mediated transgene expression peaks to remain
at maximally stable levels prior to behavioral testing (e.g., Klug-
mann et al., 2005; Klugmann and Szumlinski, 2008). Sample sizes
employed in the statistical analyses of the data ranged from 8 to
11 mice/group/AAV for both the NAC and spinal cord study.
STATISTICAL ANALYSIS
Behavioral and biochemical results are presented as means± SEM
(n= 8–12/group). Immunoblotting data were analyzed by one-
way analyses of variance (ANOVA) with Tukey’s multiple com-
parison post hoc tests and these results are presented in Table 1.
Behavioral results were analyzed by two-way ANOVA and sig-
nificant interactions were followed up by an analysis for simple
effects and Bonferroni’s multiple comparison post hoc tests, when
appropriate. To confirm significant place-conditioning, a priori
dependent-sample t -tests were conducted for the time spent in
the heroin-paired vs. -unpaired compartment, separately for each
treatment group/genotype. α= 0.05 for all analyses and the results
of the statistical analyses for the behavioral assays are presented in
their corresponding figure legends.
RESULTS
CCI ELEVATES MESOCORTICOLIMBIC PROTEIN EXPRESSION AND
ABOLISHES HEROIN CPP
Chronic constriction injury of the sciatic nerve increased mechan-
ical and cold hypersensitivity in B6 mice (Figures 1A,B). This
hypersensitivity was associated with increased expression of the
majority of our proteins of interest within all four mesocor-
ticolimbic structures investigated (as indicated in Figure 1C),
with regional distinctions in the magnitude and/or time-course
of the observed protein changes (Figure 2; see Table 1). In
the PFC (Figure 2A), CCI increased Homer1b/c, Homer2a/b,
GluN2A, and p(Tyr)p85α at both time-points post-injury, while
those for mGluR1a, GluN2B, and pPKCε were time-dependent.
In the NAC (Figure 2B), CCI increased Homer1b/c, GluN2A,
and pPKCε at both time-points, while kinase activation increased
time-dependently and the rise in mGluR5 was transient. In the
AMY (Figure 2C), the rise in mGluR5 was also transient; how-
ever, CCI increased Homer1b/c, GluN2B, PKCε, pPKCε, and
p(Tyr)p85α both time-points and ERK levels increased time-
dependently. Unfortunately, we could not detect a reliable sig-
nal for mGluR1a within our AMY samples. Finally, in the VTA
(Figure 2D), CCI increased Homer2a/b, and GluN2A at both
time-points, the rise in GluN2B, pPKCε, and the pPKCε:PKCε
ratio increased time-dependently and the rise in p(Tyr)p85α and
ERK were transient.
We next assayed for CCI-induced changes in heroin-
conditioned reward in B6 mice as an index of motivation. All
but the lowest heroin dose elicited a significant CPP in injury-
naïve B6 controls (Figure 3). In contrast, no heroin dose elicited
CPP in injured B6 mice and the 0.1-mg/kg dose elicited a sig-
nificant conditioned place-aversion (CPA). The injury-induced
abolishment of CPP did not reflect impairments in motor
activity as group differences were not observed regarding: (1)
spontaneous locomotor activity (data not shown; total dis-
tance traveled during Habituation, Pre-Test, or Post-Test; t -tests,
p> 0.05); (2) saline- or heroin-induced locomotor activity on
injection 1 or 4; or (3) the expression of heroin-induced loco-
motor sensitization, which was observed only at the 3-mg/kg
dose [data not shown; Heroin effect: F (2,48)= 25.76, p= 0.001;
Heroin× Injection: F (2,48)= 2.87, p= 0.07].
GENOTYPE×PAIN INTERACTIONS IN HEROIN CPP
Given the CCI-induced rise in Homer expression throughout
the mesocorticolimbic system, we next assayed for low-dose
heroin-induced place-conditioning in naïve and CCI Homer1a,
Homer1, and Homer2 null mutant mice, as well as in transgenic
mice with a disrupted mGluR5-Homer interaction (Grm5R/R).
The 0.1-mg/kg heroin dose elicited a significant CPP in injury-
naïve WT mice from all strains and this CPP was absent in all
homozygous mutant littermate animals (Figure 4, left). Consis-
tent with the above data from B6 mice, the 0.1-mg/kg heroin
dose elicited a significant CPA in all CCI WT mice, but this
too was attenuated or prevented in all homozygous mutant
mouse lines (Figure 4, right). Such data pose a necessary role
for Homer1a induction, as well as scaffolding by constitutively
expressed (coiled-coil) CC-Homer proteins and their interaction
with mGluR5 as critical for both heroin-related appetitive and
aversive learning.
AAV-MEDIATED HOMER GENE TRANSFER AND INJURY-INDUCED CPA
The pattern of AAV-mediated neuronal transduction within the
NAC was consistent with that reported previously by our group
(e.g., Cozzoli et al., 2009; Goulding et al., 2011), with little spread
beyond the infusion site (Figures 5A,A′′). Intra-NAC cDNA-
Homer1c and shRNA-Homer1c infusion potentiated and inhib-
ited, respectively, both mechanical and cold hypersensitivity fol-
lowing CCI, but the effect was more pronounced in the von Frey
test (Figure 5B). Neither Homer manipulation influenced basal
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Table 1 | Statistical results of the one-way ANOVAs conducted on the immunoblotting data (α=0.05) and follow-upTukey’s multiple
comparison post hoc tests, where appropriate.
Region Protein Results
ANOVA Post hoc
PFC mGluR1a F (2,23)=10.53, p=0.0007 CCI 2 weeks>CNT=CCI 1 week
mGluR5 F (2,23)=3.80, p=0.04
GluN2A F (2,21)=6.47, p=0.0007 CCI 1 week=CCI 2 weeks>CNT
GluN2B F (2,23)=10.39, p=0.0007 CCI 2 weeks>CNT=CCI 1 week
Homer1b/c F (2,21)=13.67, p=0.0002 CCI 1 week=CCI 2 weeks>CNT
Homer2a/b F (2,19)=12.51, p=0.0005 CCI 1 week=CCI 2 weeks>CNT
PKCε F (2,23)=0.32, p=0.73
pPKCε F (2,17)=3.94, p=0.04 CCI 2 weeks>CNT=CCI 1 week
pPKCε:PKCε ratio F (2,17)=2.06, p=0.16
PI3K F (2,17)=0.37, p=0.69
P(Tyr)p85α F (2,19)=8.22, p=0.003 CCI 1 week=CCI 2 weeks>CNT
ERK F (2,20)=0.06, p=0.94
pERK F (2,20)=0.06, p=0.95
pERK:ERK ratio F (2,17)=0.01, p=0.98
NAC mGluR1a F (2,17)=1.45, p=0.26
mGluR5 F (2,17)=6.97, p=0.0007 CCI 1 week>CNT=CCI 2 weeks
GluN2A F (2,17)=10.52, p=0.001 CCI 1 week=CCI 2 weeks>CNT
GluN2B F (2,17)=1.62, p=0.23
Homer1b/c F (2,17)=7.96, p=0.004 CCI 1 week=CCI 2 weeks>CNT
Homer2a/b F (2,17)=0.24, p=0.78
PKCε F (2,17)=1.71, p=0.21
pPKCε F (2,17)=7.31, p=0.006 CCI 1 week=CCI 2 weeks>CNT
pPKCε:PKCε ratio F (2,17)=7.28, p=0.006 CCI 2 weeks>CNT=CCI 1 week
PI3K F (2,17)=0.29, p=0.74
P(Tyr)p85α F (2,17)=12.25, p=0.0007 CCI 2 weeks>CNT=CCI 1 week
ERK F (2,17)=1.04, p=0.38
pERK F (2,17)=0.42, p=0.67
pERK:ERK ratio F (2,17)=7.68, p=0.005 CCI 2 weeks>CNT=CCI 1 week
AMY mGluR1a –
mGluR5 F (2,17)=12.59, p=0.0006 CCI 1 week>CNT=CCI 2 weeks
GluN2A F (2,17)=1.26, p=0.31
GluN2B F (2,17)=13.16, p=0.0005 CCI 1 week=CCI 2 weeks>CNT
Homer1b/c F (2,17)=14.41, p=0.0003 CCI 1 week=CCI 2 weeks>CNT
Homer2a/b F (2,17)=0.15, p=0.86
PKCε F (2,17)=12.65, p=0.0006 CCI 1 week=CCI 2 weeks>CNT
pPKCε F (2,17)=16.43, p=0.0002 CCI 1 week=CCI 2 weeks>CNT
pPKCε:PKCε ratio F (2,17)=0.38, p=0.68
PI3K F (2,17)=0.45, p=0.64
P(Tyr)p85α F (2,17)=13.85, p=0.0004 CCI 1 week=CCI 2 weeks>CNT
ERK F (2,17)=3.83, p=0.04 CCI 2 weeks>CNT=CCI 1 week
pERK F (2,17)=0.65, p=0.54
pERK:ERK ratio F (2,17)=1.69, p=0.21
VTA mGluR1a F (2,17)=3.63, p=0.05 CCI 1 week=CCI 2 weeks>CNT
mGluR5 F (2,17)=0.42, p=0.66
GluN2A F (2,17)=5.08, p=0.02 CCI 1 week=CCI 2 weeks>CNT
GluN2B F (2,17)=6.19, p=0.01 CCI 2 weeks>CNT=CCI 1 week
Homer1b/c F (2,17)=1.68, p=0.22
Homer2a/b F (2,17)=6.99, p=0.007
PKCε F (2,17)=0.17, p=0.84
(Continued)
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Table 1 | Continued
Region Protein Results
ANOVA Post hoc
pPKCε F (2,17)=6.29, p=0.01 CCI 2 weeks>CNT=CCI 1 week
pPKCε:PKCε ratio F (2,17)=6.22, p=0.01 CCI 2 weeks>CNT=CCI 1 week
PI3K F (2,17)=2.82, p=0.09
P(Tyr)p85α F (2,17)=3.87, p=0.04 CCI 1 week>CNT=CCI 2 weeks
ERK F (2,17)=5.31, p=0.02 CCI 1 week>CNT=CCI 2 weeks
pERK F (2,17)=0.08, p=0.92
pERK:ERK ratio F (2,17)=2, p=0.005
The data are summarized in Figure 2 and sample sizes ranged from 6 to 8 mice/group.
FIGURE 1 | Chronic constriction injury of the sciatic nerve results in
mechanical and cold hypersensitivity in B6 mice. When assessed at 3, 7,
and 14 days post-injury, B6 mice exhibited mechanical hypersensitivity as
assessed in the von Frey test (A) [CCI×Time: F (3,56) =9.07, p<0.0001] and
cold hypersensitivity as measured in the acetone test (B) [CCI×Time:
F (3,56) =10.77, p<0.0001]. The data represent the mean±SEM of 6–8
mice/group. *p<0.05 vs. naïve (control) mice (Bonferroni’s post hoc tests).
(C) Immediately following pain threshold assessments at the 1 and 2-week
time-points, tissue was obtained from the entire PFC, NAC, AMY, and the VTA
of CCI and naïve mice as indicated for processing by immunoblotting.
pain threshold to mechanical and cold stimuli (Figure 5B) nor
did they alter simple spinal pain reflex assessed in the tail-flick test
(Figure 5C).
While intra-NAC shRNA-Homer1c did not influence heroin
CPP in injury-naïve animals, it prevented injury-induced heroin
CPA (Figure 5D, left). In contrast to shRNA-Homer1c infusion,
intra-NAC cDNA-Homer1c infusion prevented heroin-induced
place-conditioning in both naïve and injured groups (Figure 5D,
right).
Intrathecal infusion of cDNA-Homer1c and -Homer2b poten-
tiates, while that of cDNA-Homer1a attenuates, CCI-induced
pain hypersensitivity (Obara et al., 2013). Thus, we determined
whether or not spinal Homer expression might also regulate
heroin place-conditioning. Intrathecal infusion of all three AAV-
cDNAs blunted heroin CPP in injury-naïve mice (Figure 6, left).
In this study, the heroin CPA exhibited by GFP-infused CCI
mice was not as robust as that observed in the experiments
above; nevertheless, none of the AAV-cDNAs influenced the extent
or direction of behavior exhibited by CCI animals (Figure 6,
right).
DISCUSSION
Pain-associated affective and motivational blunting is hypoth-
esized to involve injury-induced changes in mesocorticolimbic
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FIGURE 2 | Chronic constriction injury of the sciatic nerve augments
glutamate-related protein expression throughout the mesocorticolimbic
circuit. Summary of the changes in protein expression observed within the
PFC (A), NAC (B), AMY (C), and VTA (D) in sciatic nerve-ligated mice (CCI)
sacrificed at 1 or 2 weeks following injury, as well as in naïve controls. The
following rabbit polyclonal antibodies were used: anti-Homer 2a/b and
anti-Homer 1b/c (Dr. Paul F. Worley, Johns Hopkins University School of
Medicine; 1:1000 dilution), anti-mGluR5 (Upstate, Lake Placid, NY, USA;
1:1000 dilution), anti-GluN2A and anti-GluN2A (Calbiochem, San Diego, CA,
USA; 1:1000 dilution), anti-PI3K antibody (Upstate; 1:1000 dilution), and
anti-p-(Tyr) PI3K p85α binding motif (Cell Signaling Technology, Beverly, MA,
USA; 1:250 dilution), anti-ERK1/2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:500 dilution), anti-PKCε and anti-p(Ser729)PKCε (Santa Cruz
Biotechnology; 1:1000 dilution). Anti-mGluR1a (Upstate; 1:1000 dilution) and
anti-p(Tyr204)ERK1/2 (Santa Cruz Biotechnology; 1:1000) mouse polyclonal
antibodies were also used. A rabbit anti-calnexin monoclonal antibody
(Stressgen, Victoria, BC, Canada; 1:1000 dilution) was used as a loading and
transfer control. Immunoreactive bands were detected using enhanced
chemiluminescence and immunoreactivity quantified using Image J (NIH,
Bethesda, MD, USA). The data for neuropathic animals at the different
time-points post-CCI were expressed as a percent change from the mean
signal of the uninjured controls for each individual membrane
(n=3–4/membrane). The data represent the mean±SEM of 6–8 mice/group
and detailed results of the statistical analyses of these data are presented in
Table 1. *p<0.05 vs. naïve (control) mice (seeTable 1; one-way ANOVA
followed by Tukey’s post hoc tests).
function (c.f., Leknes and Tracey, 2008; Becker et al., 2012;
Oluigbo et al., 2012). Thus, the present study characterized
CCI-induced changes glutamate receptor expression/signaling
within four major components of the mesocorticolimbic system
and then assayed the functional relevance of mGluR5 interactions
with its scaffolding molecule Homer (Shiraishi-Yamaguchi and
Furuichi, 2007) for pain-elicited changes in heroin’s incentive
motivational properties.
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FIGURE 3 | Chronic constriction injury perturbs heroin-induced CPP in
B6 mice. Summary of the difference in the time spent (in seconds)
between the heroin-paired and -unpaired compartment on a test for
place-conditioning conducted 24 h following conditioning with 0.01, 0.1, 1,
and 3 mg/kg heroin in B6 mice. CCI significantly altered heroin CPP
[CCI×Heroin: F (1,58) =11.67, p=0.001]. Deconstruction of the interaction
along with Heroin Dose factor indicated no CCI effects at the lowest dose
of heroin, but group differences at all other doses [0.01 mg/kg: t (14) =0.20,
p=0.42; 0.1 mg/kg: t (16) =4.63, p=0.0001; 1 mg/kg: t (14) =1.31, p=0.11;
3 mg/kg: t (14) =2.58, p=0.01]. To confirm the presence or absence of
place-conditioning in each group, t -tests were conducted and verified
significant CPP in control naïve mice at doses of 0.1 mg/kg heroin or greater
[0.1 mg/kg: t (8) =5.60, p=0.001; 1 mg/kg: t (7) =2.58, p=0.04; 3 mg/kg:
t (7) = 3.90, p=0.006], while the 0.01-mg/kg dose produced a significant
CPA in CCI mice [t (9) =3.97, p=0.004]. No significant conditioning was
observed in CCI mice at the other heroin doses (p> 0.05). The data
represent the mean±SEM of 8–9 animals/group/dose. *p<0.05 vs. naïve
control; +p<0.05 vs. 0 min (Bonferroni’s post hoc tests or t -test).
NEUROPATHY AUGMENTS INDICES OF MESOCORTICOLIMBIC
GLUTAMATE TRANSMISSION
Chronic constriction injury-induced hypersensitivity was associ-
ated with up-regulated mesocorticolimbic glutamate receptor and
CC-Homer expression, as well as increased indices of ERK, PI3K,
and/or PKCε activity. The present PFC data replicate our ear-
lier study (Obara et al., 2013), indicating that injury up-regulates
glutamate receptor signaling within a forebrain region important
for volitional control over behavior, cognition, and emotion (c.f.,
Arnsten and Rubia, 2012; Depue, 2012). CCI-induced increases
in protein expression were observed also within VTA, NAC, and
AMY, with some regional differences that are not to be unexpected.
However, CCI elevated Homer1b/c levels and PI3K activation
in all mesocorticolimbic regions examined. Homer proteins are
involved in the recruitment of PI3K-enhancer to Group1 mGluRs
to induce PI3K activity (Rong et al., 2003). PI3K induction, at least
within spinal cord, contributes to the development of neuropathic
pain hypersensitivity (Xu et al., 2011). As an intra-NAC infu-
sion of cDNA-Homer1c was sufficient to promote CCI-induced
pain hypersensitivity, injury-induced increases in mesocorticolim-
bic Homer-dependent PI3K activity may contribute significantly
to somatic and affective pain chronification following peripheral
nerve injury. Indeed, certain AMY subregions receive direct and
indirect nociceptive input from spinal cord, brainstem, thalamus,
and cortex (c.f., Leknes and Tracey, 2008; Becker et al., 2012).
Moreover, central sensitization, via signaling pathways involving
ERK, PKCs, and PI3K, occurs within this structure in various mod-
els of chronic pain (c.f., Neugebauer et al., 2004; Neugebauer, 2006;
Fu et al., 2008; Tappe-Theodor et al., 2011). Our observation of
up-regulated protein expression within AMY could reflect a central
sensitization of mesocorticolimbic activity that would be predicted
to elicit negative emotional disturbances characteristic of chronic
pain sufferers.
While we failed to detect a significant reduction in VTA
ERK activity following CCI, previous studies indicated reduced
VTA ERK activation and c-fos expression following injury, which
was interpreted to reflect blunted VTA responsiveness and the-
orized to contribute to pain-induced amotivational states (e.g.,
Narita et al., 2003, 2004; Ozaki et al., 2004). However, CCI ele-
vated our other indices of signaling within VTA, most notably
GluN2 subunits, Homer2a/b, activated PKCε, and PI3K, which
would be predicted to elevate, rather than depress, basal activ-
ity of mesolimbic dopamine neurons to heighten the saliency
of both conditioned and unconditioned pain cues (Berridge,
2007; Bromberg-Martin et al., 2010). Indeed, these present
immunoblotting results are consistent with human neuroimag-
ing data indicating correlations between heightened PFC-NAC
connectivity and pain chronification (Baliki et al., 2010, 2012).
Thus, injury-induced plasticity within corticofugal glutamatergic
and mesocorticolimbic dopaminergic projections might heighten
PFC-NAC connectivity predictive of somatic and affective pain
chronification. In support of this notion, NAC Homer1c expres-
sion bi-directionally altered CCI-induced pain symptoms, with
increased Homer1c promoting nociception in CCI mice (see
below).
HEROIN CPP AND HOMER-mGluR5 INTERACTIONS
In all experiments, repeated low-dose (0.1 mg/kg) heroin consis-
tently supported CPP in injury-naïve WT mice. Remarkably, this
low-dose heroin CPP was attenuated or absent in injury-naïve
mice from all four mutant strains. Opioids and their withdrawal
alter Homer1 gene products within the PFC and AMY (Ammon
et al., 2003; Kuntz et al., 2008) and recently, polymorphisms in
Homer1, as well as changes in striatal and AMY Homer1 mRNA
expression, were reported in post-mortem studies of heroin
addicts (Okvist et al., 2011; Jacobs et al., 2012). While constitu-
tive Homer2 deletion does not impact heroin-induced locomotor
activity (Szumlinski et al., 2004), to the best of our knowledge,
these data are the first to describe the heroin reward phenotype
produced by constitutive deletion of different Homer genes or
transgenic disruption of mGluR5-Homer interactions. That null
mutations of Homer1a and Homer1 (the latter of which elim-
inates both inducible and CC Homer1 isoforms; see Yuan et al.,
2003) produced a more pronounced effect upon conditioning than
Homer2 deletion argues a more critical role forHomer1 gene prod-
ucts, particularly Homer1a, in this form of heroin-related learning.
Moreover, the fact that Grm5R/R mice not only failed to exhibit
heroin CPP, but tended toward CPA, argues further that the inter-
action between Homer1 gene products and mGluR5 is fundamen-
tal to the motivational valence of low-dose heroin, which is worthy
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FIGURE 4 | Mutations affecting mGluR5-Homer interactions blunt
heroin CPP and reverse the effects of CCI upon heroin CPA.
Summary of the difference in the time spent in the heroin-paired and
-unpaired compartments (CPP) following conditioning with 0.1 mg/kg
heroin in mice with constitutive deletion of Homer1a, Homer1, or
Homer2, and in mice expressing the Grm5R/R transgene. Analysis of the
data from all of the mutant animals revealed significant Genotype×CCI
interactions [Homer1a: F (2,64) =3.50, p= 0.04; Homer1: F (2,67) = 6.10,
p=0.004; Homer2: F (2,66) =4.14, p=0.02; Grm5R/R: F (2,101) =6.71,
p=0.002]. (A) In uninjured mice from the Homer1a study, a priori
t -tests (time on paired vs. unpaired side) confirmed significant CPP in
Homer1a WT [t (10) =8.43, p<0.0001; n=11], but no place-conditioning
was evidence in their HET or KO counterparts (t -tests, p’s>0.50,
n=13–15). In CCI mice from the Homer1a study, CPA was apparent in
WT controls (t (10) =2.81, p=0.02; n=11), but again no conditioning
was apparent in their HET or KO counterparts (t -tests, p>0.65;
n=8–12). (B) As observed in the Homer1a study, heroin elicited CPP
and CPA, respectively in uninjured and CCI Homer1 WT mice [naïve:
t (9) =6.12, p<0.0001; CCI: t (10) =2.34, p=0.04], while no significant
place-conditioning was apparent under either condition in HET or KO
mice (n=11–13; t -tests, p>0.12). (C) Heroin elicited CPP and CPA,
respectively, in uninjured and CCI Homer2 WT mice [naïve: t (9) =3.18,
p= 0.01; CCI: t (7) =2.76, p= 0.03]. No place-conditioning was apparent
in HET mice under either condition (n= 15; t -tests, p>0.90). While
uninjured Homer2 KO mice did not exhibit CPP (n=11; t -test, p=0.15),
CPP, not CPA, was apparent in their CCI counterparts [t (7) =3.27,
p=0.01]. (D) Heroin elicited also CPP and CPA, respectively, in naïve
and CCI mice Grm5F/F mice (i.e., WT) [naïve: t (21) =4.90, p< 0.0001;
CCI: t (18) =3.00, p=0.08], while no significant place-conditioning was
apparent in Grm5F/R or Grm5R/R mutants (n=12–18; t -tests,
p>0.20). *p<0.05 Paired vs. unpaired (i.e., conditioning; t -tests);
+p<0.05 vs. WT control (Tukey’s post hoc tests).
of further exploration. The Grm5R/R data are interesting as the
effect of mGluR5 antagonism upon opioid-induced CPP is incon-
sistent (Popik and Wróbel, 2002; McGeehan and Olive, 2003; van
der Kam et al., 2009). As the Grm5R/R mutation does not impact
total receptor expression (Cozzoli et al., 2009), the present behav-
ioral observations implicate intracellular signaling processes that
are known to be modulated by dynamic changes in Homer1a/CC-
Homer interactions with mGluR5 in the positive incentive moti-
vational properties of heroin-paired cue/contexts. Such signaling
processes include (but are not likely limited to): altered regula-
tion of voltage-gated ion channels, constitutive mGluR5 activity,
induction of PI3K activity, and mGluR-dependent regulation of
NMDA receptor current (c.f., Shiraishi-Yamaguchi and Furuichi,
2007). While the precise biochemical mechanisms mediating the
blunted heroin CPP exhibited by Homer mutant and Grm5R/R
mice obviously require detailed study that are beyond the scope
of this report, the results of larger-scale dose-response studies of
cocaine or alcohol CPP argue that this heroin phenotype does
not reflect a mere impairment of associative learning processes
(Szumlinski et al., 2004, 2005; Datko et al., 2008; Goulding et al.,
2009). Unfortunately, cessation of breeding programs for the var-
ious mutant lines precludes a full dose-response analysis of heroin
CPP. Thus, it remains to be determined whether or not the blunted
low-dose heroin CPP observed in injury-naïve Homer1a/1/2 or
Grm5R/R mutant mice reflects changes in the sensitivity or effi-
cacy of heroin to elicit conditioned reward or if the blunted CPP
extends to any other measure of heroin reward/reinforcement.
However, arguing against increased sensitivity to heroin intoxica-
tion as a mechanism underpinning the blunted heroin CPP, all
mutant lines exhibited WT-levels of heroin-induced locomotion
throughout testing.
Interestingly, Homer1 deletion abolished low-dose heroin CPP,
while intra-NAC shRNA-Homer1c infusion had absolutely no
effect. These data indicate either that: (1) the neural locus
mediating the CPP effect of Homer1 deletion resides outside
the NAC or (2) the CPP effect of Homer1 deletion reflect
an absence of inducible, rather than constitutively expressed,
Homer1 gene products. As the effects of Homer1a deletion mir-
rored those of Homer1 deletion argues in favor of the lat-
ter possibility. However, based on suggestions of regional dif-
ferences in heroin-induced changes in Homer1 mRNA within
PFC, AMY, and dorsal striatum (Kuntz et al., 2008; Okvist
et al., 2011; Jacobs et al., 2012), Homer1 gene products in
these other addiction-relevant brain regions may contribute
more so to the conditioned incentive motivational properties of
low-dose heroin. It is interesting to note, however, that intra-
NAC cDNA-Homer1c, as well as intrathecal cDNA-Homer1a,
-Homer1c, and -Homer2b infusion, in injury-naïve mice was
sufficient to block heroin CPP. The result for the NAC may
be counterintuitive based on the findings from the KO stud-
ies, but, as argued below, may reflect a facilitation of low-dose
heroin hyperalgesia that renders the heroin experience more
aversive.
INJURY-INDUCED HEROIN CPA ALSO REQUIRES INTACT
mGluR5-HOMER INTERACTIONS
Most notable and distinct from the results of earlier CPP stud-
ies in injured animals (c.f., Niikura et al., 2010), neuropathic B6
mice exhibited CPA in response to 0.1 mg/kg heroin – a dose
of heroin that supported CPP in uninjured animals. In WT
mice, CCI clearly augmented pain symptoms prior to heroin
conditioning (see also Obara et al., 2013), supporting a causal
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FIGURE 5 | Homer1c in the NAC bi-directionally influences neuropathic
pain symptoms and heroin CPA. (A) Half coronal section of the mouse brain
at the level of the NAC targeted in the AAV infusion studies. (A′) Micrograph
(4×) of GFP staining within the NAC shell produced by the shRNA-Homer1c
construct [see box in (A) for orientation]. (A′′) Micrograph (20×) of
immunostaining for the HA-tagged cDNA-Homer1c construct within NAC shell
illustrating both cell body and process staining in the tissue surrounding the
microinjector tip (bracket). At 3 weeks following intra-NAC infusion, mice were
subjected to CCI procedures, followed by behavioral testing. (B) Relative to
GFP vector controls (GFP), altering NAC Homer1c expression bi-directionally
altered both mechanical hypersensitivity assessed in the von Frey test
[AAV×Time ANOVA: F (2,130) =150.6, p<0.0001] and cold hypersensitivity
assessed in the acetone test [AAV×Time ANOVA: F (2,130) = 93.27, p<0.0001].
*p<0.05 vs. GFP. (C) No changes in the tail-flick test were observed following
intra-NAC AAV infusion (one-way ANOVA, p=0.38). (D) An AAV×CCI
interaction was observed for heroin-induced place-conditioning [F (2,52) =3.79,
p=0.03]. In GFP controls, cDNA-Homer1c over-expression prevented heroin
CPP, while shRNA-Homer1c was without effect [F (2,28) =3.36, p= 0.04;Tukey’s
post hoc tests].T -tests confirmed the presence of a significant CPP in GFP
controls [t (9) = 4.20, p=0.002] and shRNA-infused control animals [t (9) =3.49,
p=0.007]. In contrast, both Homer1c manipulations attenuated heroin CPA in
CCI mice [F (2,24) =7.37, p= 0.003; Tukey’s post hoc tests].T -tests confirmed a
significant CPA in scrambled controls [t (9) =3.49, p=0.007], but no
conditioning in Homer1c-manipulated animals (t -tests, p>0.05). *p<0.05
Paired vs. unpaired (conditioning; t -tests); #p<0.05 vs. scrambled AAV. The
data represent the mean±SEM of 8–11 mice/AAV/condition.
relation between pain symptomatology and low-dose heroin aver-
sion. In further support of a direct cause-effect relation between
pain and heroin aversion, cDNA-Homer1 infusion into either the
NAC or spinal cord augments pain hypersensitivity and abolishes
heroin CPP in injury-naive animals. Furthermore, intra-NAC
shRNA-Homer1c infusion, a manipulation that reduced pain
hypersensitivity following CCI, prevented subsequent heroin CPA.
However, neither intra-NAC nor intrathecal cDNA-Homer1c
infusion potentiated heroin CPA in CCI animals. In fact, NAC
cDNA-Homer1c transduction in CCI mice attenuated heroin CPA,
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FIGURE 6 | Spinal Homer over-expression alters heroin-induced
place-conditioning. Summary of the effects of intrathecal administration
of AAVs carrying cDNA for Homer1a, Homer1c, or Homer2b upon
place-conditioning elicited by 0.1 mg/kg in naïve (control) and CCI mice.
Analyses of these data revealed a main CCI effect [F (1,70) =12.82,
p=0.001], but interaction with the AAV factor (p=0.28). A priori t -tests
confirmed a significant CPP in naïve mice infused with GFP [t (8) = 5.60,
p=0.001], but no CPP in any of the cDNA-infused naïve groups (t -tests,
p’s>0.05). In this study, we observed only a modest CPA in CCI-GFP
controls [t (8) = 2.05, p=0.08], as well as in cDNA-Homer1c infused CCI
mice [t (9) =1.84, p=0.09], while no evidence for conditioning was observed
in cDNA-Homer1a or cDNA-Homer2b CCI mice (p’s>0.20). The data
represent the mean±SEM of 8–10 mice/AAV/condition. *p<0.05 Paired
vs. unpaired (conditioning; t -tests).
although the magnitude of place-conditioning was not statisti-
cally different from GFP-infused CCI controls. These data, cou-
pled with the lack of any significant cDNA effect in our spinal
cord study (where weak CPA was observed in CCI mice) argue
against a ceiling effect limiting the expression of CCI-induced
CPA. Arguably, however, the fact that the effects of cDNA-Homer
infusion upon heroin place-conditioning were not additive with
those produced by CCI alone might be interpreted to reflect
mechanistic interdependency,an interpretation that would be con-
sistent with the notion that CCI-induced increases in glutamate
receptor/Homer expression are neuroadaptations that promote
dysphoric states.
Indeed, the present data from the studies of transgenic mice
support this possibility as no evidence for CCI-induced heroin
CPA was apparent in any mutant strain; in fact, both Homer1
and Homer2 KO mice exhibited conditioned approach behav-
ior following nerve injury. That both Homer1a deletion and the
Grm5R/R transgene exacerbate neuropathic pain symptoms, while
neither Homer1 nor Homer2 deletion influence pain hypersensi-
tivity (Obara et al., 2013), argues that the severity of neuropathic
pain symptoms is not a determinant of CCI-induced deficits in
heroin CPP (Table 2). CCI-induced neuropathy likely involves
temporally dynamic changes in inducible vs. constitutive Homer
expression, with early post-injury elevations in inducible Homers
facilitating synaptic rearrangement that is later maintained by
injury-induced increases in CC-Homer expression (e.g., Miletic
et al., 2005, 2009; Miyabe et al., 2006; Tappe et al., 2006; Ma
et al., 2009; Obara et al., 2013). Thus, the genetic interruption
Table 2 | Comparison of the effects of constitutive gene mutations
affecting mGluR5-Homer interactions or AAV-mediated changes in
Homer expression upon the development of neuropathic pain
symptoms following CCI, the expression of a low-dose heroin CPP,
and the heroin CPA observed in CCI animals (present study; Obara
et al., 2013)1.
Gene manipulation CCI pain
symptoms
Heroin
CPP
CCI-induced
heroin CPA
CONSTITUTIVE GENE MUTATION
Homer1a KO ↑1 ↓ ↓
Homer1 KO No effect1 ↓ ↓
Homer2 KO No effect1 ↓ ↓ (Full reversal)
Grm5R/R ↑1 ↓ ↓
AAV-MEDIATED GENETRANSFER
NAC cDNA-Homer1c ↑ ↓ ↓
NAC shRNA-Homer1c ↓ No effect ↓
IT cDNA-Homer1a ↓1 ↓ No effect
IT cDNA-Homer1c ↑1 ↓ No effect
IT cDNA-Homer2b ↑1 ↓ No effect
CCI, chronic constriction injury of the sciatic nerve; CPA, conditioned place-
aversion; CPP, conditioned place-preference; IT, intrathecal; NAC, intra-nucleus
accumbens.
of the temporal dynamics of the interplay between inducible
and CC-Homer protein expression at glutamate receptors, and
likely other Homer-interacting molecules, while not always suf-
ficient to prevent neuroplasticity within pain pathways, appears
to be sufficient to prevent whatever mesocorticolimbic neuro-
plasticity mediating CCI-induced deficits in heroin-conditioned
reward. Given the present data, it becomes important to char-
acterize more systematically: (1) how heroin dose interacts with
a chronic pain state to influence drug reward/reinforcement
and to relate these interactions to the expression of different
Homer isoforms, as well as their major interacting partners
throughout the central nervous system; (2) to extrapolate find-
ings for heroin to prescription opioid drugs employed in pain
management, and importantly; (3) to examine the relevance
of injury-induced changes in glutamate receptor/Homer expres-
sion for the incentive motivational properties of opioid and
other non-opioid analgesic drugs (e.g., cannabinoids). Arguably,
such lines of investigation will enable a better understanding
of the molecular and cellular processes mediating pain-induced
dysphoria, which has relevance not only for therapeutic inter-
vention of pain-induced negative affective states, but also indi-
vidual vulnerability to develop abuse or addiction during pain
management with opioid or non-opioid drugs with high abuse
potential.
ACKNOWLEDGMENTS
This research was supported by funds from UCSB, as well as NIH
grants DA024038 and AA016650 to Karen K. Szumlinski, NIH
grants DA11742 and DA10309 to Paul F. Worley, and by funds
from UNSW, as well as the Australian Research Council Future
Fellowship to Matthias Klugmann.
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol June 2013 | Volume 4 | Article 39 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obara et al. Pain and heroin place-conditioning
REFERENCES
Ammon, S., Mayer, P., Riechert, U.,
Tischmeyer, H., and Hollt, V.
(2003). Microarray analysis of
genes expressed in the frontal
cortex of rats chronically treated
with morphine and after nalox-
one precipitated withdrawal.
Brain Res. Mol. Brain Res. 112,
113–125. doi:10.1016/S0169-
328X(03)00057-3
Arnsten, A. F., and Rubia, K. (2012).
Neurobiological circuits regulat-
ing attention, cognitive control,
motivation, and emotion: disrup-
tions in neurodevelopmental psychi-
atric disorders. J. Am. Acad. Child
Adolesc. Psychiatry 51, 356–367.
doi:10.1016/j.jaac.2012.01.008
Ary, A. W., Lominac, K. D., Wroten,
M. G., Williams, A. R., Campbell,
R. R., Ben-Shahar, O., et al. (2013).
Imbalances in prefrontal cortex
CC-Homer1 versus CC-Homer2
expression promote cocaine pref-
erence. J. Neurosci. 33, 8101–8113.
doi:10.1523/JNEUROSCI.1727-
12.2013
Baliki, M. N., Geha, P. Y., Fields, H.
L., and Apkarian, A. V. (2010). Pre-
dicting value of pain and analgesia:
nucleus accumbens response to nox-
ious stimuli changes in the presence
of chronic pain.Neuron 66, 149–160.
doi:10.1016/j.neuron.2010.03.002
Baliki, M. N., Petre, B., Torbey, S., Her-
rmann, K. M., Huang, L., Schnitzer,
T. J., et al. (2012). Corticostri-
atal functional connectivity pre-
dicts transition to chronic back
pain. Nat. Neurosci. 15, 1117–1119.
doi:10.1038/nn.3153
Becker, S., Gandhi, W., and Schwein-
hardt, P. (2012). Cerebral
interactions of pain and reward
and their relevance for chronic
pain. Neurosci. Lett. 520, 182–187.
doi:10.1016/j.neulet.2012.03.013
Berridge, K. C. (2007). The debate over
dopamine’s role in reward: the case
for incentive salience. Psychophar-
macology (Berl.) 191, 391–431.
doi:10.1007/s00213-006-0578-x
Bromberg-Martin, E. S., Matsumoto,
M., and Hikosaka, O. (2010).
Dopamine in motivational con-
trol: rewarding, aversive, and
alerting. Neuron 68, 815–834.
doi:10.1016/j.neuron.2010.11.022
Chiechio, S., and Nicoletti, F. (2012).
Metabotropic glutamate receptors
and the control of chronic pain.
Curr. Opin. Pharmacol. 12, 28–34.
doi:10.1016/j.coph.2011.10.010
Colpaert, F. C., Meert, T., De Witte, P.,
and Schmitt, P. (1982). Further evi-
dence validating adjuvant arthritis as
an experimental model of chronic
pain in the rat. Life Sci. 31, 67–75.
doi:10.1016/0024-3205(82)90402-7
Colpaert, F. C., Taraye, J. P., Alliaga,
M., Bruins Slot, L. A., Attal, N.,
and Koek, W. (2001). Opioid self-
administration as a measure of
chronic nociceptive pain in arthritic
rats. Pain 91, 33–45. doi:10.1016/
S0304-3959(00)00413-9
Cozzoli, D. K., Goulding, S. P., Zhang,
P. W., Xiao, B., Hu, J. H., Ary, A.
W., et al. (2009). Binge drinking
upregulates accumbens mGluR5-
Homer2-PI3K signaling: functional
implications for alcoholism. J. Neu-
rosci. 29, 8655–8668. doi:10.1523/
JNEUROSCI.5900-08.2009
Datko, M. C., Hu, J.-H., Williams, M.,
Reyes, C., Seeburg, P. H., Schwarz,
M. K., et al. (2008). The induction
of Homer1a is necessary for cocaine-
induced neuroplasticity. Soc. Neu-
rosci. Abstr. 767.10.
Depue, B. E. (2012). A neuroanatomical
model of prefrontal inhibitory mod-
ulation of memory retrieval. Neu-
rosci. Biobehav. Rev. 36, 1382–1399.
doi:10.1016/j.neubiorev.2012.02.012
Dib, B., and Duclaux, R. (1982). Intrac-
erebroventricular self-injection of
morphine in response to pain
in the rat. Pain 13, 395–406.
doi:10.1016/0304-3959(82)90008-2
Doth, A. H., Hansson, P. T., Jensen,
M. P., and Taylor, R. S. (2010). The
burden of neuropathic pain: a sys-
tematic review and meta-analysis of
health utilities. Pain 149, 338–344.
doi:10.1016/j.pain.2010.02.034
Fu, Y., Han, J., Ishola, T., Scerbo, M.,
Adwanikar, H., Ramsey, C., et al.
(2008). PKA and ERK, but not
PKC, in the amygdala contribute
to pain-related synaptic plasticity
and behavior. Mol. Pain 4, 26.
doi:10.1186/1744-8069-4-26
Goulding, S. P., Bergin, M., Hu, J. H.,
Worley, P. F., and Szumlinski, K. K.
(2009). Evidence that the negative
regulator of Group1 mGluR func-
tion Daughter of Homer (DOH)
is necessary for high-dose alcohol
reward in mice. Alcohol. Clin. Exp.
Res. 33(Suppl. 1), 75A.
Goulding, S. P., Obara, I., Lominac,
K. D., Gould, A. T., Miller, B.
W., Klugmann, M., et al. (2011).
Accumbens Homer2-mediated sig-
naling: a factor contributing to
mouse strain differences in alco-
hol drinking? Genes Brain Behav.
10, 111–126. doi:10.1111/j.1601-
183X.2010.00647.x
Harris, R. E., and Clauw, D. J.
(2012). Imaging central neu-
rochemical alterations in
chronic pain with proton mag-
netic resonance spectroscopy.
Neurosci. Lett. 520, 192–196.
doi:10.1016/j.neulet.2012.03.042
Hu, J. H., Yang, L., Kammermeier, P. J.,
Moore, C. G., Brakeman, P. R., Tu,
J., et al. (2012). Preso1 dynamically
regulates group I metabotropic glu-
tamate receptors. Nat. Neurosci. 15,
836–844. doi:10.1038/nn.3103
Jacobs, M. M., Okvist, A., Horvath, M.,
Keller, E., Bannon, M. J., Morgello,
S., et al. (2012). Dopamine recep-
tor D1 and postsynaptic density
gene variants associate with opi-
ate abuse and striatal expression
levels. Mol. Psychiatry (in press).
doi:10.1038/mp.2012.140
Jarcho, J. M., Mayer, E. A., Jiang,
Z. K., Feier, N. A., and Lon-
don, E. D. (2012). Pain, affective
symptoms, and cognitive deficits
in patients with cerebral dopamine
dysfunction. Pain 153, 744–754.
doi:10.1016/j.pain.2012.01.002
Kalivas, P. W. (2009). The glutamate
homeostasis hypothesis of addic-
tion.Nat. Rev.Neurosci. 10, 561–572.
doi:10.1038/nrn2515
Klugmann, M., Symes, C. W., Leichtlein,
C. B., Klaussner, B. K., Dunning,
J., Fong, D., et al. (2005). AAV-
mediated hippocampal expression
of short and long Homer 1 pro-
teins differentially affect cognition
and seizure activity in adult rats.
Mol. Cell. Neurosci. 28, 347–360.
doi:10.1016/j.mcn.2004.10.002
Klugmann, M., and Szumlinski, K.
K. (2008). Targeting Homer genes
using adeno-associated viral vector:
lessons learned from behavioural
and neurochemical studies. Behav.
Pharmacol. 19, 485–500. doi:10.
1097/FBP.0b013e32830c369f
Kuntz, K. L., Patel, K. M., Grigson, P.
S., Freeman, W. M., and Vrana, K. E.
(2008). Heroin self-administration:
II. CNS gene expression follow-
ing withdrawal and cue-induced
drug-seeking behavior. Pharma-
col. Biochem. Behav. 90, 349–356.
doi:10.1016/j.pbb.2008.03.019
Kuroda, R., Yorimae, A., Yamada,
Y., Nakatani, J., and Takatsuji, K.
(1995). c-Fos expression after for-
malin injection into the face in the
cat. Stereotact. Funct. Neurosurg. 65,
152–156. doi:10.1159/000098686
Leknes, S., and Tracey, I. (2008). A
common neurobiology for pain and
pleasure. Nat. Rev. Neurosci. 9,
314–320. doi:10.1038/nrn2333
Lyness, W. H., Smith, F. L., Heavner,
J. E., Iacono, C. U., and Garvin,
R. D. (1989). Morphine self-
administration in the rat during
adjuvant-induced arthritis. Life Sci.
45, 2217–2224. doi:10.1016/0024-
3205(89)90062-3
Ma, Z. L., Zhu, W., Zhang, W., and Gu,
X. P. (2009). Effect of the synap-
tic scaffolding protein Homer1a on
chronic compression of dorsal root
ganglion. Ann. Clin. Lab. Sci. 39,
71–75.
Martin, T. J., Buechler, N. L., Kim, S. A.,
Ewan, E. E., Xiao, R., and Childers,
S. R. (2011). Involvement of the lat-
eral amygdala in the antiallodynic
and reinforcing effects of heroin in
rats after peripheral nerve injury.
Anesthesiology 114, 633–642. doi:10.
1097/ALN.0b013e318209aba7
Martin, T. J., Kim, S. A., Buechler, N.
L., Porreca, F., and Eisenach, J. C.
(2007). Opioid self-administration
in the nerve injured rat: relevance
of antiallodynic effects to drug con-
sumption and effects of intrathecal
analgesics. Anesthesiology 106,
312–322. doi:10.1097/00000542-
200702000-00020
McGeehan,A. J., and Olive, M. F. (2003).
The mGluR5 antagonist MPEP
reduces the conditioned rewarding
effects of cocaine but not other
drugs of abuse. Synapse 47, 240–242.
doi:10.1002/syn.10166
Miletic, G., Driver, A. M., Miyabe-
Nishiwaki, T., and Miletic, V. (2009).
Early changes in Homer1 pro-
teins in the spinal dorsal horn
are associated with loose ligation
of the rat sciatic nerve. Anesth.
Analg. 109, 2000–2007. doi:10.
1213/ANE.0b013e3181beea9b
Miletic, G., Miyabe, T., Gebhardt, K.
J., and Miletic, V. (2005). Increased
levels of Homer1b/c and Shank1a
in the post-synaptic density of
spinal dorsal horn neurons are asso-
ciated with neuropathic pain in
rats. Neurosci. Lett. 386, 189–193.
doi:10.1016/j.neulet.2005.06.007
Minozzi, S., Amato, L., and Davoli, M.
(2013). Development of depen-
dence following treatment with
opioid analgesics for pain relief:
a systematic review. Addiction
108, 688–698. doi:10.1111/j.1360-
0443.2012.04005.x
Miyabe, T., Miletic, G., and Miletic,
V. (2006). Loose ligation of the
sciatic nerve in rats elicits tran-
sient up-regulation of Homer1a
gene expression in the spinal dorsal
horn. Neurosci. Lett. 398, 296–299.
doi:10.1016/j.neulet.2006.01.011
Narita, M., Kishimoto, Y., Ise, Y., Yajima,
Y., Misawa, K., and Suzuki, T. (2005).
Direct evidence for the involve-
ment of the mesolimbic kappa-
opioid system in the morphine-
induced rewarding effect under an
inflammatory pain-like state. Neu-
ropsychopharmacology 30, 111–118.
doi:10.1038/sj.npp.1300527
www.frontiersin.org June 2013 | Volume 4 | Article 39 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obara et al. Pain and heroin place-conditioning
Narita, M., Oe, K., Kato, H., Shibasaki,
M., Narita, M., Yajima, Y., et al.
(2004). Implication of spinal pro-
tein kinase C in the suppression of
morphine-induced rewarding effect
under a neuropathic pain-like state
in mice. Neuroscience 125, 545–551.
doi:10.1016/j.neuroscience.2004.
02.022
Narita, M., Ozaki, S., Narita, M.,
Ise, Y., Yajima, Y., and Suzuki, T.
(2003). Change in the expres-
sion of c-fos in the rat brain
following sciatic nerve ligation.
Neurosci. Lett. 352, 231–233.
doi:10.1016/j.neulet.2003.08.052
Neugebauer, V. (2006). “Subcortical
processing of nociceptive informa-
tion: basal ganglia and amygdala,”
in Pain, eds F. Cervero and T.
S. Jensen (Amsterdam: Elsevier),
141–158.
Neugebauer, V., Li, W., Bird, G.
C., and Han, J. S. (2004). The
amygdala and persistent pain.
Neuroscientist 10, 221–234.
doi:10.1177/1073858403261077
Niikura, K., Narita, M., Butelman, E. R.,
Kreek, M. J., and Suzuki, T. (2010).
Neuropathic and chronic pain stim-
uli downregulate central mu-opioid
and dopaminergic transmission.
Trends Pharmacol. Sci. 31, 299–305.
doi:10.1016/j.tips.2010.04.003
Obara, I., Goulding, S. P., Hu, J.
H., Klugmann, M., Worley, P. F.,
and Szumlinski, K. K. (2013).
Nerve injury-induced changes
in Homer/glutamate receptor
signaling contribute to devel-
opment and maintenance of
neuropathic pain. Pain (in press).
doi:10.1016/j.pain.2013.03.035
Obara, I., Mika, J., Schafer, M. K.,
and Przewlocka, B. (2003). Antag-
onists of the kappa-opioid recep-
tor enhance allodynia in rats and
mice after sciatic nerve ligation.
Br. J. Pharmacol. 140, 538–546.
doi:10.1038/sj.bjp.0705427
Ohayon, M. M., and Schatzberg,
A. F. (2010). Chronic pain
and major depressive disor-
der in the general population.
J. Psychiatr. Res. 44, 454–461.
doi:10.1016/j.jpsychires.2009.10.013
Okvist, A., Fagergren, P., Whittard, J.,
Garcia-Osta, A., Drakenberg, K.,
Horvath, M. C., et al. (2011). Dys-
regulated postsynaptic density and
endocytic zone in the amygdala of
human heroin and cocaine abusers.
Biol. Psychiatry 69, 245–252.
doi:10.1016/j.biopsych.2010.09.037
Olive, M. F., Cleva, R. M., Kali-
vas, P. W., and Malcolm, R. J.
(2012). Glutamatergic medications
for the treatment of drug and
behavioral addictions. Pharmacol.
Biochem. Behav. 100, 801–810.
doi:10.1016/j.pbb.2011.04.015
Oluigbo, C. O., Salma, A., and Rezai, A.
R. (2012). Targeting the affective and
cognitive aspects of chronic neu-
ropathic pain using basal forebrain
neuromodulation: rationale, review
and proposal. J. Clin. Neurosci.
19, 1216–1221. doi:10.1016/j.jocn.
2012.04.002
Osikowicz, M., Mika, J., Makuch, W.,
and Przewlocka, B. (2008). Gluta-
mate receptor ligands attenuate allo-
dynia and hyperalgesia and poten-
tiate morphine effects in a mouse
model of neuropathic pain. Pain
139, 117–126.
Osikowicz, M., Mika, J., and
Przewlocka, B. (2013). The
glutamatergic system as a tar-
get for neuropathic pain relief.
Exp. Physiol. 98, 372–384. doi:10.
1113/expphysiol.2012.069922
Ozaki, S., Narita, M., Narita, M.,
Iino, M., Miyoshi, K., and Suzuki,
T. (2003). Suppression of the
morphine-induced rewarding
effect and G-protein activation
in the lower midbrain follow-
ing nerve injury in the mouse:
involvement of G-protein-coupled
receptor kinase 2. Neuroscience
116, 89–97. doi:10.1016/S0306-
4522(02)00699-1
Ozaki, S., Narita, M., Narita, M.,
Ozaki, M., Khotib, J., and Suzuki,
T. (2004). Role of extracellular
signal-regulated kinase in the ven-
taral tegmental area in the sup-
pression of the morphine-induced
rewarding effect in mice with sci-
atic nerve ligation. J. Neurochem.
88, 1389–1397. doi:10.1046/j.1471-
4159.2003.02272.x
Penzner, J. H., Thompson, D. L.,
Arth, C., Fowler, J. K., Ary, A.
W., and Szumlinski, K. K. (2008).
Protracted “anti-addictive” phe-
notype produced in C57BL/6J
mice by adolescent phenyl-
propanolamine treatment. Addict.
Biol. 13, 310–325. doi:10.1111/
j.1369-1600.2008.00101.x
Popik, P., and Wróbel, M. (2002).
Morphine conditioned reward is
inhibited by MPEP, the mGluR5
antagonist. Neuropharmacology 43,
1210–1217. doi:10.1016/S0028-
3908(02)00309-X
Rodella, L., Rezzani, R., Gioia, G.,
Tredici, G., and Bianchi, R. (1998).
Expression of fos immunore-
activity in the rat supraspinal
regions following noxious vis-
ceral stimulation. Brain Res. Bull.
47, 357–366. doi:10.1016/S0361-
9230(98)00123-3
Rong, R., Ahn, J. Y., Huang, H.,
Nagata, E., Kalman, D., Kapp,
J. A., et al. (2003). PI3 kinase
enhancer-Homer complex couples
mGluRI to PI3 kinase, preventing
neuronal apoptosis. Nat. Neurosci. 6,
1153–1161. doi:10.1038/nn1134
Shin, D. M., Dehoff, M., Luo, X.,
Kang, S. H., Tu, J., Nayak, S.
K., et al. (2003). Homer 2 tunes
G protein-coupled receptors stim-
ulus intensity by regulating RGS
proteins and PLCbeta GAP activ-
ities. J. Cell Biol. 162, 293–303.
doi:10.1083/jcb.200210109
Shiraishi-Yamaguchi, Y., and Furuichi,
T. (2007). The Homer family
proteins. Genome Biol. 8, 206.
doi:10.1186/gb-2007-8-2-206
Szumlinski, K. K., Ary, A. W., and
Lominac, K. D. (2008). Homers
regulate drug-induced neuroplas-
ticity: implications for addiction.
Biochem. Pharmacol. 75, 112–133.
doi:10.1016/j.bcp.2007.07.031
Szumlinski, K. K., Dehoff, M.
H., Kang, S. H., Frys, K. A.,
Lominac, K. D., Rohrer, J.,
et al. (2004). Homer pro-
teins regulate vulnerability to
cocaine. Neuron 43, 401–413.
doi:10.1016/j.neuron.2004.07.019
Szumlinski, K. K., Lominac, K. D., Ole-
son, E. B., Walker, J. K., Mason,
A., Dehoff, M. H., et al. (2005).
Homer2 is necessary for ethanol-
induced neuroplasticity. J. Neu-
rosci. 25, 7054–7061. doi:10.1523/
JNEUROSCI.1529-05.2005
Tappe, A., Klugmann, M., Luo, C.,
Hirlinger, D., Agarwal, N., Ben-
rath, J., et al. (2006). Synaptic
scaffolding protein Homer1a pro-
tects against chronic inflamma-
tory pain. Nat. Med. 12, 677–681.
doi:10.1038/nm1406
Tappe-Theodor, A., Fu, Y., Kuner,
R., and Neugebauer, V. (2011).
Homer1a signaling in the amyg-
dala counteracts pain-related synap-
tic plasticity, mGluR1 function and
pain behaviors. Mol. Pain 7, 38.
doi:10.1186/1744-8069-7-38
van der Kam, E. L., De Vry, J.,
and Tzschentke, T. M. (2009). 2-
Methyl-6-(phenylethynyl)-pyridine
(MPEP) potentiates ketamine
and heroin reward as assessed
by acquisition, extinction, and
reinstatement of conditioned
place preference in the rat.
Eur. J. Pharmacol. 606, 94–101.
doi:10.1016/j.ejphar.2008.12.042
Wood, P. B., Schweinhardt, P., Jaeger,
E., Dagher, A., Hakyemez, H.,
Rabiner, E. A., et al. (2007).
Fibromyalgia patients show an
abnormal dopamine response
to pain. Eur. J. Neurosci. 25,
3576–3582. doi:10.1111/j.1460-
9568.2007.05623.x
Wozniak, K. M., Rojas, C.,
Wu, Y., and Slusher, B. S.
(2012). The role of glu-
tamate signaling in pain
processes and its regulation by
GCP II inhibition. Curr.
Med. Chem. 19, 1323–1334.
doi:10.2174/092986712799462630
Xu, Q., Fitzsimmons, B., Steinauer, J.,
O’Neill,A., Newton,A. C., Hua, X. Y.,
et al. (2011). Spinal phosphinositide
3-kinase-Akt-mammalian target
of rapamycin signaling cascades
in inflammation-induced hyperal-
gesia. J. Neurosci. 31, 2113–2124.
doi:10.1523/JNEUROSCI.2139-
10.2011
Yuan, J. P., Kiselyov, K., Shin, D.
M., Chen, J., Shcheynikov, N.,
Kang, S. H., et al. (2003). Homer
binds TRPC family channels
and is required for gating of
TRPC1 by IP3 receptors. Cell
114, 777–789. doi:10.1016/S0092-
8674(03)00716-5
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 05 March 2013; paper pend-
ing published: 18 March 2013; accepted:
10 May 2013; published online: 07 June
2013.
Citation: Obara I, Goulding SP, Gould
AT, Lominac KD, Hu J-H, Zhang
PW, von Jonquieres G, Dehoff M, Xiao
B, Seeburg PH, Worley PF, Klug-
mann M and Szumlinski KK (2013)
Homers at the interface between reward
and pain. Front. Psychiatry 4:39. doi:
10.3389/fpsyt.2013.00039
This article was submitted to Frontiers
in Addictive Disorders and Behavioral
Dyscontrol, a specialty of Frontiers in
Psychiatry.
Copyright © 2013 Obara, Goulding ,
Gould, Lominac, Hu, Zhang , von Jon-
quieres, Dehoff, Xiao, Seeburg , Worley,
Klugmann and Szumlinski. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol June 2013 | Volume 4 | Article 39 | 12
